Electronic Journal of General Medicine

Declaration of Conflict of Interest: No conflict of interest is declared by author(s).

• Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 2018; pii: S2213-8587(18)30154-2. https://doi.org/10.1016/S2213-8587(18)30154-2.
• Wang JK, Feng ZW, Li YC, Li QY, Tao XY. Association of tumor necrosis factor-α gene promoter polymorphism at sites -308 and -238 with non-alcoholic fatty liver disease: A meta-analysis. J Gastroenterol Hepatol 2012;27(4):670–6. https://doi.org/10.1111/j.1440-1746.2011.06978.x.
• Seo YY, Cho YK, Bae JC, Seo MH, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Lee WY. Tumor necrosis factor-α as a predictor for the development of nonalcoholic fatty liver disease: A 4-year follow-up study. Endocrinol Metab (Seoul) 2013;28(1):41–5. https://doi.org/10.3803/EnM.2013.28.1.41.
• Tilg H, Moschen AR, Szabo G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 2016;64(3):955-65. https://doi.org/10.1002/hep.28456.
• Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol 2015;12(7): 387-400. https://doi.org/10.1038/nrgastro.2015.94.
• Gieling RG, Wallace K, Han YP. Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol 2009;296(6): G1324-31. https://doi.org/10.1152/ajpgi.90564.2008.
• Tack CJ, Stienstra R, Joosten LA, Netea MG. Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family. Immunol Rev2012;249(1):239-52. https://doi.org/10.1111/j.1600-065X.2012.01145.x.
• Negrin KA, Roth Flach RJ, DiStefano MT, Matevossian A, Friedline RH, Jung D, Kim JK, Czech MP. IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. PLoS One 2014;9(9):e107265. https://doi.org/10.1371/journal.pone.0107265.
• Yamaoka-Tojo M, Tojo T, Wakaume K, Kameda R, Nemoto S, Takahira N, Masuda T, Izumi T. Circulating interleukin-18: a specific biomarker for atherosclerosis-prone patients with metabolic syndrome. Nutr Metab (Lond) 2011;8:3. https://doi.org/10.1186/1743-7075-8-3.
• Fang T, Di Y, Li G, Cui X, Shen N, Li Y, et al. Effects of telmisartan on TNFα induced PPARγ phosphorylation and insulin resistance in adipocytes. Biochem Biophys Res Commun 2018;503(4):3044-9. https://doi.org/10.1016/j.bbrc.2018.08.091.
• Chen T, Xing J, Liu Y. Effects of telmisartan on vascular endothelial function, inflammation and insulin resistance in patients with coronary heart disease and diabetes mellitus. Exp Ther Med 2018;15(1):909-13. https://doi.org/10.3892/etm.2017.5451.
• Wei X, Hu CC, Zhang YL, Yao SL, Mao WK. Telmisartan reduced cerebral edema by inhibiting NLRP3 inflammasome in mice with cold brain injury. J Huazhong Univ Sci Technolog Med Sci 2016; 36(4):576-83. https://doi.org/10.1007/s11596-016-1628-1.
• Arumugam S, Sreedhar R, Thandavarayan RA, Giridharan VV, Karuppagounder V, Pitchaimani V, Afrin R, Harima M, Nakamura T, Ueno K, Nakamura M, Suzuki K, Watanabe K. Telmisartan treatment targets inflammatory cytokines to suppress the pathogenesis of acute colitis induced by dextran sulphate sodium. Cytokine 2015;74(2):305-12. https://doi.org/10.1016/j.cyto.2015.03.017.
• Song Z, Bai J, Zhang L, Sun X, Zhang M, Zheng H, Zhang J. Effects of telmisartan on inflammation and fibrosis after acute myocardial infarction in rats]. Zhonghua Yi Xue Za Zhi 2014; 94(33):2628-33.
• Zhang QZ, Liu YL, Wang YR, Fu LN, Zhang J, Wang XR, Wang BM. Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease. Exp Ther Med 2017;14(3):2689-94. https://doi.org/10.3892/etm.2017.4809.
• Kudo H, Yata Y, Takahara T, Kawai K, Nakayama Y, Kanayama M, Oya T, Morita S, Sasahara M, Mann DA, Sugiyama T. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int 2009; 29(7):988-96. https://doi.org/10.1111/j.1478-3231.2009.02006.x.
• Alam S, Kabir J, Mustafa G, Gupta U, Hasan SK, Alam AK. Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial. Saudi J Gastroenterol 2016;22(1):69-76. https://doi.org/10.4103/1319-3767.173762.
• Borém LMA, Neto JFR, Brandi IV, Lelis DF, Santos SHS. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertens Res 2018;41(6):394-405. https://doi.org/10.1038/s41440-018-0040-6.
• Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991;43(1):26-31. https://doi.org/10.1016/S0009-9260(05)80350-2.
• Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123(3):745-50. https://doi.org/10.1053/gast.2002.35354.
• Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0.5 could be a suitable global boundary value. Nutr Res Rev 2010;23(2): 247–69. https://doi.org/10.1017/S0954422410000144.
• Mazidi M, Kengne AP, Katsiki N, Mikhailidis DP, Banach M. Lipid accumulation product and triglycerides/glucose index are useful predictors of insulin resistance. J Diabetes Complications 2018;32(3):266-70. https://doi.org/10.1016/j.jdiacomp.2017.10.007.
• Sterling RK, Lissen E, Clumeck N, , Sola R, Correa MC, Montaner J, et al.. Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology 2006;43(6):1317-25. https://doi.org/10.1002/hep.21178.
• Rotundo L, Persaud A, Feurdean M, Ahlawat S, Kim HS. The Association of leptin with severity of non-alcoholic fatty liver disease: A population-based study. Clin Mol Hepatol. 2018 Aug 2. https://doi.org/10.3350/cmh.2018.0011.
• Fallatah HI, Akbar HO, Fallatah AM. Fibroscan compared to FIB-4, APRI, and AST/ALT Ratio for assessment of liver fibrosis in Saudi patients with nonalcoholic fatty liver disease. Hepat Mon 2016;16(7):e38346. https://doi.org/10.5812/hepatmon.38346.
• Zhu D, Bays H, Gao P, Mattheus M, Voelker B, Ruilope LM. Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, gender, race, hypertension severity, and previous antihypertensive use: planned analyses of a randomized trial. Integr Blood Press Control 2013; 6:1-14. https://doi.org/10.2147/IBPC.S33104.
• Choi GJ, Kim HM, Kang H, Kim J. Effects of telmisartan on fat distribution: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2016; 32(7):1303-9. https://doi.org/10.1185/03007995.2016.1171204.
• Bochar OM. Combined effect of appointment telmisartan and atorvastatin on hemodynamic indicators and the indicators of lipid profile in patients with arterial hypertension combined with obesity and steatohepatitis. Wiad Lek. 2014;67(2 Pt 2):157-60.
• Wang Y, Qiao S, Han DW, Rong XR, Wang YX, Xue JJ, Yang J. Telmisartan improves insulin resistance: A meta-analysis. Am J Ther 2018 Mar 16. https://doi.org/10.1097/MJT.0000000000000733.
• Mahmood IH, Abed MN, Merkhan MM. Effects of blocking of angiotensin system on the prevalence of metabolic syndrome in type 2 diabetic patients. Pak J Med Sci 2013;29(1):140-3. https://doi.org/10.12669/pjms.291.2782.
• Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009;15(8):942-54. https://doi.org/10.3748/wjg.15.942.
• Nanji AA, French SW, Freeman JB. Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients. Enzyme 1986;36(4):266-9. https://doi.org/10.1159/000469304.
• Ionică FE, Mogoantă L, Negreş S, Bejenaru LE, Cristea OM, Badea O, Bejenaru C.. Comparing the antifibrotic effect on the liver of telmisartan and pentoxifylline, in a Wistar rat experimental model. Rom J Morphol Embryol 2017;58(4):1237-48.
• Ionică FE, Mogoantă L, Nicola GC, ChiriŢă C, Negreş S, Bejenaru C, Turculeanu A, Badea O, Popescu NL, Bejenaru LE. Antifibrotic action of telmisartan in experimental carbon tetrachloride-induced liver fibrosis in Wistar rats. Rom J Morphol Embryol 2016;57(4):1261-72.
• Kanda T, Matsuoka S, Yamazaki M, Shibata T, Nirei K, Takahashi H, Kaneko T, Fujisawa M, Higuchi T, Nakamura H, Matsumoto N, Yamagami H, Ogawa M, Imazu H, Kuroda K, Moriyama M. Apoptosis and non-alcoholic fatty liver diseases. World J Gastroenterol 2018; 24(25):2661-72. https://doi.org/10.3748/wjg.v24.i25.2661.
• Del Campo JA, Gallego P, Grande L. Role of inflammatory response in liver diseases: Therapeutic strategies. World J Hepatol. 2018;10(1):1-7. https://doi.org/10.4254/wjh.v10.i1.1.

Vancouver

Al-Nimer MS, Esmail VA, Mohammad O. Telmisartan improves the metabolic, hematological and inflammasome indices in non-alcoholic fatty liver infiltration: A pilot open-label placebo-controlled study. ELECTRON J GEN MED. 2019;16(3):em142. https://doi.org/10.29333/ejgm/104568

APA

Al-Nimer, M. S., Esmail, V. A., & Mohammad, O. (2019). Telmisartan improves the metabolic, hematological and inflammasome indices in non-alcoholic fatty liver infiltration: A pilot open-label placebo-controlled study. Electronic Journal of General Medicine, 16(3), em142. https://doi.org/10.29333/ejgm/104568

AMA

Al-Nimer MS, Esmail VA, Mohammad O. Telmisartan improves the metabolic, hematological and inflammasome indices in non-alcoholic fatty liver infiltration: A pilot open-label placebo-controlled study. ELECTRON J GEN MED. 2019;16(3), em142. https://doi.org/10.29333/ejgm/104568

Chicago

Al-Nimer, Marwan S.M., Vian A.W. Esmail, and O. Mohammad. "Telmisartan improves the metabolic, hematological and inflammasome indices in non-alcoholic fatty liver infiltration: A pilot open-label placebo-controlled study". Electronic Journal of General Medicine 2019 16 no. 3 (2019): em142. https://doi.org/10.29333/ejgm/104568

Harvard

Al-Nimer, M. S., Esmail, V. A., and Mohammad, O. (2019). Telmisartan improves the metabolic, hematological and inflammasome indices in non-alcoholic fatty liver infiltration: A pilot open-label placebo-controlled study. Electronic Journal of General Medicine, 16(3), em142. https://doi.org/10.29333/ejgm/104568

MLA

Al-Nimer, Marwan S.M. et al. "Telmisartan improves the metabolic, hematological and inflammasome indices in non-alcoholic fatty liver infiltration: A pilot open-label placebo-controlled study". Electronic Journal of General Medicine, vol. 16, no. 3, 2019, em142. https://doi.org/10.29333/ejgm/104568